Infinity Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Cambridgemassachusettsfounded In 1995The Company Focuses On Developing Innovative Small Molecule Therapeutics For Cancer Treatmentparticularly In The Field Of Immuno Oncologytheir Research Targets Mechanisms To Reprogram The Tumor Microenvironment To Enhance Anti Tumor Immune Responses The Company S Key Producteganelisibipi 549 Is An Orally Administered Pi3K Gamma Inhibitor Currently In Phase 2 Trials For Metastatic Triple Negative Breast Cancer And Urothelial Canceras Well As Phase 1 1B Trials For Solid Tumorsinfinity Has Also Collaborated With Other Organizationsincluding Roche And Bristol Myers Squibbto Advance Its Clinical Development Effortstheir Therapies Are Aimed At Oncology Patientsespecially Those With Advanced Solid Tumors And Cancers That Are Resistant To Existing Treatments
